Drugs.com - Monthly Update August 2026

In our August 2026 episode of Drugs.com Monthly Update, we review the latest round of FDA approvals bringing new therapeutic strategies to patients and prescribers.mFLUSIVA (influenza vaccine, mRNA): A new mRNA-based seasonal flu vaccine approved for the prevention of influenza disease in adults 50 years of age and older.Orzeyful (oveporexton): An innovative orexin receptor 2 agonist approved for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients.Genglycos (pariglasgene brecaparvovec-opnr): A novel gene therapy for adults and pediatric patients 8 years and older with glycogen storage disease type Ia to reduce daily cornstarch intake.Rasonque (daraxonrasib): A broad RAS-targeted medicine approved for previously treated adults with metastatic pancreatic adenocarcinoma.Bixlenvo (bictegravir and lenacapavir): A once-daily combination antiretroviral tablet for virologically suppressed adults with HIV-1 replacing their current regimen.Chapters:(00:19) - Intro (00:48) - mFLUSIVA (01:45) - Orzeyful (02:41) - Genglycos (03:45) - Rasonque (04:46) - Bixlenvo (05:47) - Outro Follow Drugs.com:X, Facebook, YouTubeSign up to our newslettersDownload the app